InflaRx N.V.
- IFRX
- NASDAQ
- Biotechnology
- C5a Inhibitors
- Inflammation/Autoimmune Biotech
- Clinical-Stage Therapies
$1.32
Today −8.33%Quote Oct 16, 2026, 08:00 PM UTC
−35.92%over the last month
Max drawdown −37.7%From 1-month high −37.7%3 months −27.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$95.4M
Quote Oct 16
Next earnings
Nov 9
Expected, not confirmed
Analyst target
$9.00
+581.8% from here
Floor
$1.31
1.1% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about IFRXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
65